Biochemical progression-free survival in localized prostate cancer patients treated with definitive external beam radiotherapy
Keywords:
prostate cancer, progression-free survival, definitive radiotherapy, prostate specific antigenAbstract
Introduction: Prostate cancer is now the third most frequent noncutaneous malignancy in Iranian men and the fifth most common cancer worldwide. Measurement of total serum prostate specific antigens (PSAs) has been one of the strongest predictors of biochemical progression and overall survival in determining the efficacy of definitive external beam radiation therapy in patients with localized prostate cancer. The aim of this research was to identify the 5-year biochemical progression-free survival (BFS) and related prognostic and predictive factors of localized prostate cancer patients who were treated with definitive external beam radiotherapy.
Methods: This study analyzed 192 localized prostate cancer patients from stage T1aN0M0 to stage T3N0M0; they were treated with definitive radiation therapy and followed up in the radiation-oncology ward of Shohada-e-Tajrish Hospital in Tehran (Iran) between 2006 and 2013. The 5-year BFS was analyzed using the Kaplan-Meier estimate. For multivariate analysis, the Cox proportional hazards model was used to assess the strengths of various factors for 5-year BFS.
Results: The follow-up period was between 14-81 months, with a median of 31 months. The median cumulative prostate dose in our series was 64 Gray (Gy) (range 62 to 78 Gy). The 5-year BFS for all patients was 65.1%, and 5-year BFS in low-risk, intermediate-risk and high-risk groups were 100%, 86.5%, and 54.9% respectively. Multivariate analysis found statistically significant relation between 5-year BFS and initial PSA>20, Gleason score 8-10, high risk group, TNM stage≥T2cN0M0, radiotherapy dose<70 Gy, radiotherapy with 2D technique and hormonal therapy in high-risk group (p=0.003, p=0.032, p=0.014, p=0.001, p=0.035, p=0.035, p=0.022 respectively).
Conclusion: Our seven years’ experience of follow-up with PSA showed that PSA was the strongest predictor of biochemical progression survival in patients with prostate cancer who were treated with definitive external beam radiation therapy.
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin
; 61:69-90. Doi: 10.3322/caac.20107, PMID: 21296855
Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate-specific antigen in patients with prostate
cancer. J Urol. 1989; 142: 1011-1017. PMID: 2477559
Fischer K, Loertzer H and Fornara P: The use of complexed PSA for the early detection of prostate cancer.
Anticancer Res25: 1591-1596, 2005. PMID: 16033065
Ludwig JA and Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev
Cancer 5: 845-856, 2005. Doi: 10.1038/nrc1739. PMID: 16239904
Bartsch G, Catalona W, Gospodarowicz M. Developments in the treatment of localized prostate cancer. In:
McConnell J, Dennis L, Akaza H, Khoury S, Schalken J, editors. Prostate cancer: 6th international
consultation on new developments in prostate cancer and prostate diseases. Paris: Health Publication; 2006:
-308.
Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, et al. Long-term survival after
radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer
; 117: 2883-91. Doi: 10.1002/cncr.25900. PMID: 21692049. PMCID: PMC3139725
Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, et al. Prostate cancer, Version
2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw2012; 10: 1081-7. PMID:
D'Amico AV, Chen MH, Oh-Ung J, Renshaw AA, Cote K, Loffredo M, et al. Changing prostate-specific
antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific
antigen era. Int J Radiat Oncol Biol Phys 2002; 54: 436-41. Doi: 10.1016/S0360-3016(02)02940-1
The American Society for Therapeutic Radiology and Oncology Consensus Panel and Cox JD: Consensus
Statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37: 1035-1041,
PMID: 9169810
Kestin LL, Vicini FA, Ziaja EL, et al. Defining biochemical cure for prostate carcinoma patients treated
with external beam radiation therapy. Cancer. 1999; 86:1557-1566. Doi: 10.1002/(SICI)1097- 0142(19991015)86:8<1557::AID-CNCR24>3.0.CO;2-2
Lee WR, Hanlon AL and Hanks GE: Prostate-specific antigen nadir following external beam radiation
therapy for clinically localized prostate cancer: The relationship between nadir level and disease free
survival. J Urol 156: 450-453, 1996. Doi: 10.1016/S0022-5347(01)65876-2. PMID: 8683700
Hanks GE, Perez CA, Kozar M, Asbell SO, Pilepich MV and Pajak TF: PSA confirmation of cure at 10
years of T1b, T2, N0, M0 prostate cancer patients treated in RTOG Protocol 7706 with external beam
irradiation. Int J Radiat Oncol Biol Phys 30: 289-292, 1994. Doi: 10.1016/0360-3016(94)90006-X
Roach M 3rd, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D, Lawton C, Shipley W
and Cox J: Predicting long-term survival and the need for hormonal therapy: a meta-analysis of RTOG
prostate cancer trials. Int J Radiat Oncol Biol Phys 47: 617-627, 2000. Doi: 10.1016/S0360- 3016(00)00577-0
Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomized trial comparing
conventionaldose with high-dose conformal radiation therapy in earlystage adenocarcinoma of the prostate:
long-term results from proton radiation oncology group/american college of radiology95-09. J Clin Oncol
; 28:1106-11. Doi: 10.1200/JCO.2009.25.8475. PMID: 20124169. PMCID: PMC2834463
Freedland SJ, Hotaling JM, Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, et al. PSA in the new
millennium: a powerful predictor of prostate cancer prognosis and outcomes: results from the SEARCH
database. Eur Urol2008; 53:758-64. Doi: 10.1016/j.eururo.2007.08.047. PMID: 17868976
Published
Issue
Section
License
Copyright (c) 2020 knowledge kingdom publishing
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
